Literature DB >> 9305898

Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.

Z Ji1, E M Hadac, R M Henne, S A Patel, T P Lybrand, L J Miller.   

Abstract

Mechanisms of ligand binding and activation of G protein-coupled receptors are particularly important, due to their ubiquitous expression and potential as drug targets. Molecular interactions between ligands and these receptors are best defined for small molecule ligands that bind within the transmembrane helices. Extracellular domains seem to be more important for peptide ligands, based largely on effects of receptor mutagenesis, where interference with binding or activity can reflect allosteric as well as direct effects. We now take the more direct approach of photoaffinity labeling the active site of the cholecystokinin (CCK) receptor, using a photolabile analogue of CCK having a blocked amino terminus. This probe, 125I-desaminotyrosyl-Gly-[Nle28,31, pNO2-Phe33]CCK-(26-33), binds specifically, saturably, and with high affinity (Ki = 3.3 nM) and has full agonist activity. This makes likely its being sited in a natural position within the receptor. As substrate, we used CHO-CCK receptor cells overexpressing functional recombinant rat type A CCK receptor. Covalent labeling of the appropriate Mr = 85,000-95,000 plasma membrane glycoprotein with core of Mr = 42,000 was established by SDS-polyacrylamide gel electrophoresis and autoradiography. A single domain adjacent to transmembrane 1 was labeled, as established by cyanogen bromide cleavage and separation by gel and/or high pressure liquid chromatography. The site of interaction was further defined by additional proteolysis with trypsin, with purification of the labeled fragment, followed by manual Edman degradation and radiochemical sequencing. This demonstrated that Trp39 was specifically labeled and likely resides proximate to the carboxyl-terminal pNO2-Phe33 residue of the probe. A model of this ligand-bound receptor has been constructed and will be used to plan future experiments to refine our understanding of this interaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305898     DOI: 10.1074/jbc.272.39.24393

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Role of gastrointestinal hormones in feeding behavior and obesity treatment.

Authors:  Timothy Sean Kairupan; Haruka Amitani; Kai-Chun Cheng; Joshua Runtuwene; Akihiro Asakawa; Akio Inui
Journal:  J Gastroenterol       Date:  2015-09-07       Impact factor: 7.527

2.  Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

Authors:  V Gigoux; B Maigret; C Escrieut; S Silvente-Poirot; M Bouisson; J A Fehrentz; L Moroder; D Gully; J Martinez; N Vaysse; A D Fourmy
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

3.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Authors:  Elizabeth M Hadac; Eric S Dawson; James W Darrow; Elizabeth E Sugg; Terry P Lybrand; Laurence J Miller
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

Review 4.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

5.  Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2008-05-08       Impact factor: 4.436

6.  Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.

Authors:  Laurence J Miller; Quan Chen; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Maoqing Dong
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

7.  Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Erin E Cawston; Laurence J Miller
Journal:  Assay Drug Dev Technol       Date:  2011-03-11       Impact factor: 1.738

8.  Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Keiko Hosohata; Andrew Orry; Patrick M Sexton; Ruben Abagyan; Laurence J Miller
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

9.  Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

10.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.